EGRX

Eagle Pharmaceuticals, Inc. (EGRX) | Rumor.io

Eagle Pharmaceuticals

EGRX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about EGRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Oct 4

$EGRX is considered an "expert market" stock, potentially plummeting to 10 cents or less within a month.
The company's stock is dropping, and some investors are speculating about the possibility of a successful exit or a complete loss.
There are concerns about the company's management and insiders attempting to recoup losses by taking the stock to the Pink Sheets market.

Generated by AI

Sentiment

Of the messages about EGRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	50% -7.45
Bearish	—	—	—	50% +7.45

Bullish· Nov 2

$EGRX has the potential to reach $97.00 based on a recent price target raise.
The stock's low price-to-earnings ratio of 35.8 suggests it has room to grow further.
A short call on $EGRX resulted in a gain of $2,231, indicating the stock's potential for significant price increases.

Bearish· Jul 26

$EGRX is burning through cash, with $8.5 million in monthly burn as of March 31, leaving it with $27 million in cash.
$EGRX has a history of significant price drops, with a previous instance of a similar decline resulting in a substantial loss of value.
$EGRX is facing a potentially negative market reaction due to analyst downgrades, with a predicted market capitalization of $400-600 million.

Generated by AI

Topics

Of the messages about EGRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	97.47%
Controversies	—	—	—	2.53%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Nov 1

Eagle Pharmaceuticals (EGRX) reported Q3 earnings of $1.18 EPS, missing the estimate by 7 cents.
The company missed revenue estimates, reporting $51.34M in revenue.
EGRX beat the Estimize EPS consensus by 11 cents, but missed the Estimize revenue consensus by $7.65M.

Analysts· Jul 27

Piper Jaffray Companies set a price target of $118.00 for Eagle Pharmaceuticals, Inc. ($EGRX) with a buy rating.
Mizuho Securities cut the price target for Eagle Pharmaceuticals, Inc. ($EGRX) to $40.00 with an underperform rating.
Royal Bank Of Canada lowered the price target for Eagle Pharmaceuticals, Inc. ($EGRX) to $81.00 with an outperform rating.

Announcements· Dec 19

Eagle Pharmaceuticals, Inc. (EGRX) receives FDA approval for an additional indication for PEMFEXY in combination with pembrolizumab and platinum chemotherapy.
The approval is for a new use of PEMFEXY, which is already approved for the treatment of non-small cell lung cancer.
This new indication is expected to expand the potential market for PEMFEXY and may lead to increased sales for Eagle Pharmaceuticals.

Generated by AI

Community

Of the messages about EGRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	32.41%
Newcomers	—	—	—	67.59%

Regulars· Oct 2

Eagle Pharmaceuticals' financial statements for 2022 and 2023 are being restated due to a material weakness in its internal control over financial reporting, specifically related to the recognition of revenue from the sale of PEMFEXY.
The company's failure to file key financial reports has led to its delisting from Nasdaq on October 3, 2024, and it is expected to sell assets to pay off its $75M debt.
The impact of the restatement on the company's financials may be mitigated by the fact that revenue will be added back in future periods, and the company has adequate current assets to navigate potential lawsuits or breaches of loan covenants.

Newcomers· Oct 2

Eagle Pharmaceuticals, Inc. received a notice to delist its common stock from Nasdaq, effective October 3, 2024.
The company has identified "one or more" material weaknesses in its financial reporting, according to a regulatory filing from September 27.
Eagle Pharmaceuticals shares are trading lower after the company announced it will be delisted from the Nasdaq, with trading halted multiple times due to volatility.

Generated by AI

Also Discussed

Investors talking about EGRX also mention

#	Name	Attention
1	Supernus Pharmaceuticals, Inc.SUPN	0%new
2	Pacira BioSciences, Inc.PCRX	0%new
3	Enanta Pharmaceuticals, Inc.ENTA	0%0
4	RDUS - Radius Recycling, Inc.	——
5	Agios Pharmaceuticals, Inc.AGIO	0%0
6	Puma Biotechnology, Inc.PBYI	0%0
7	Halozyme Therapeutics Inc.HALO	0%0
8	Neurocrine Biosciences, Inc.NBIX	0%new
9	BioMarin Pharmaceutical IncBMRN	0%+0
10	BDSI - BioDelivery Sciences International, Inc.	——